Division of Cardiology, Duke University Medical Center, 2301 Erwin Road, Durham, NC 27710, USA.
Duke Clinical Research Institute, Duke University School of Medicine, 300 W Morgan Street, Durham, NC 27701, USA.
Eur Heart J. 2023 Jun 1;44(21):1910-1923. doi: 10.1093/eurheartj/ehad133.
Severe tricuspid regurgitation (TR) exhibits high 1-year morbidity and mortality, yet long-term cardiovascular risk overall and by subgroups remains unknown. This study characterizes 5-year outcomes and identifies distinct clinical risk profiles of severe TR.
Patients were included from a large US tertiary referral center with new severe TR by echocardiography based on four-category American Society of Echocardiography grading scale between 2007 and 2018. Patients were categorized by TR etiology (with lead present, primary, and secondary) and by supervised recursive partitioning (survival trees) for outcomes of death and the composite of death or heart failure hospitalization. The Kaplan-Meier estimates and Cox regression models were used to evaluate any association by (i) TR etiology and (ii) groups identified by survival trees and outcomes over 5 years. Among 2379 consecutive patients with new severe TR, median age was 70 years, 61% were female, and 40% were black. Event rates (95% confidence interval) were 30.9 (29.0-32.8) events/100 patient-years for death and 49.0 (45.9-52.2) events/100 patient-years for the composite endpoint, with no significant difference by TR etiology. After applying supervised survival tree modeling, two separate groups of four phenoclusters with distinct clinical prognoses were separately identified for death and the composite endpoint. Variables discriminating both outcomes were age, albumin, blood urea nitrogen, right ventricular function, and systolic blood pressure (all P < 0.05).
Patients with newly identified severe TR have high 5-year risk for death and death or heart failure hospitalization. Partitioning patients using supervised survival tree models, but not TR etiology, discriminated clinical risk. These data aid in identifying relevant subgroups in clinical trials of TR and clinical risk/benefit analysis for TR therapies.
重度三尖瓣反流(TR)具有较高的 1 年发病率和死亡率,但总体和亚组的长期心血管风险尚不清楚。本研究描述了 5 年的结果,并确定了重度 TR 的不同临床风险特征。
本研究纳入了 2007 年至 2018 年间因超声心动图显示新出现的重度 TR 而在一家大型美国三级转诊中心接受治疗的患者。患者根据美国超声心动图学会四级分级量表分为四级,并根据 TR 病因(带导联、原发性和继发性)和有监督递归分区(生存树)进行分类,以评估死亡和死亡或心力衰竭住院的复合终点。使用 Kaplan-Meier 估计和 Cox 回归模型评估(i)TR 病因和(ii)生存树和 5 年内结果确定的组之间的任何关联。在 2379 例新诊断为重度 TR 的连续患者中,中位年龄为 70 岁,61%为女性,40%为黑人。死亡的事件发生率(95%置信区间)为 30.9(29.0-32.8)/100 患者年,复合终点的事件发生率为 49.0(45.9-52.2)/100 患者年,两组之间无显著差异。在应用有监督的生存树模型后,分别为死亡和复合终点识别出两组具有不同临床预后的四个表型聚类。区分这两个结果的变量是年龄、白蛋白、尿素氮、右心室功能和收缩压(均 P<0.05)。
新诊断为重度 TR 的患者在 5 年内死亡和死亡或心力衰竭住院的风险较高。使用有监督的生存树模型对患者进行分组,但不是 TR 病因,可以区分临床风险。这些数据有助于在 TR 临床试验中确定相关亚组,并对 TR 治疗的临床风险/获益进行分析。